Evidence map›Paper›PMID 40902202›Full record

ArticleJMIR cancer2025

Burden and Future Trends of Gastric Cancer in 5 East Asian Countries From 1990 to 2036: Epidemiological Study Analysis Using the Global Burden of Diseases Study 2021.

Tianhao Guo, Tingting Zhou, Wenjie Zhu, Yumo Yuan, Yifan Hui, Wenjian Zhu, Weixing Shen, Liu Li, Wei Wei, Haibo Cheng and 1 more

Abstract read
In one paragraph

Article in JMIR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Current status ofFujita medical journal · 2026
    Article
  2. Atypical acuteFujita medical journal · 2026
    Article
  3. Article
  4. Article
  5. [Analysis of disease burden, attributable risk factors of low back pain in China from 1990 to 2023 and prediction for 2030].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tianhao Guo *Department of Surgical Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine), 155 Hanzhong Road, Nanjing, Jiangsu, 210029, China, 86 13805168644.ORCID 0000-0002-8899-2328
Tingting Zhou *Department of Gastroenterology, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.ORCID 0009-0007-3880-4935
Wenjie Zhu *Department of Surgical Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine), 155 Hanzhong Road, Nanjing, Jiangsu, 210029, China, 86 13805168644.ORCID 0009-0004-9677-3047
Yumo Yuan *School of Elderly Care Services and Management, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0008-3446-2402
Yifan HuiJiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0003-0364-9449
Wenjian ZhuJiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0002-5292-661X
Weixing ShenJiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0002-6454-3296
Liu LiJiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0003-3369-3117
Wei WeiDepartment of Gastroenterology, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.ORCID 0000-0001-8572-921X
Haibo ChengJiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0003-3329-2225
Xiaoyu WuDepartment of Surgical Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine), 155 Hanzhong Road, Nanjing, Jiangsu, 210029, China, 86 13805168644.ORCID 0009-0005-3878-3471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Effective prevention and treatment are urgently needed, since gastric cancer (GC) poses a grave threat to the health and well-being of patients. The 5 East Asian countries (China, Japan, North Korea, South Korea, and Mongolia) represent one of the most significant regions globally in terms of GC burden. Objective: The goal of this study is to examine the patterns and trends of GC across 5 East Asian countries between 1990 and 2021. Methods: We retrieved data from the Global Burden of Disease Study (GBD) 2021 regarding the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) associated with GC in 5 East Asian countries from 1990 to 2021. We further assessed the burden of GC according to age and sex. We used decomposition analysis to examine the changes in the number of new cases, patients, and deaths related to GC. We also used Joinpoint (Joinpoint Regression Program, Version 5.1.0) and age-period-cohort analysis methods to interpret the epidemiological characteristics of GC. Autoregressive integrated moving average model (ARIMA) and Bayesian age-period-cohort (BAPC) prediction models were used to forecast the GC burden by 2036. Results: Among the 5 East Asian countries, China recorded the highest incidence, prevalence, death, YLLs, YLDs, and DALYs in both 1990 and 2021. From 1990 to 2021, the age-standardized rates for prevalence, mortality, incidence, YLDs, YLLs, and DALYs across the 5 East Asian countries showed an overall decline, though they remained higher than the global average. In all 5 East Asian countries, individuals aged 65 years and older consistently exhibited the highest rates for prevalence, incidence, mortality, YLDs, YLLs, and DALYs. The prevalence rate in South Korea, the incidence rate in North Korea and Mongolia, and the mortality rate in China are influenced by aging, surpassing the global aging average. Conclusions: The disease burden of GC in the 5 East Asian countries has consistently ranked high over the past 3 decades, particularly among the older individuals. The burden of GC in the 5 East Asian countries is expected to present a major public health challenge, primarily driven by the large population size and the aging demographic.

Indexed as

Stomach NeoplasmsAdultAgedAged, 80 and overAsia, EasternCost of IllnessDisability-Adjusted Life YearsEast Asian PeopleFemaleGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedPrevalenceQuality-Adjusted Life Yearsage-period-cohort analysisdisease burdenepidemiological studygastric cancerglobal burden of disease studyjoinpoint regression analysisprediction model

Identifiers

PMID40902202
PMCPMC12408060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.